Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin
Gwo‐Yaw Ho(The University of Melbourne), Holly E. Barker(The University of Melbourne), Cassandra J. Vandenberg(The University of Melbourne), Elizabeth Lieschke(The University of Melbourne), Ratana Lim(The University of Melbourne), Hasan Mirza(London Cancer), Ngee Kiat Chua(Walter and Eliza Hall Institute of Medical Research), Olga Kondrashova(QIMR Berghofer Medical Research Institute), Andrew Farrell(University of Utah), Anthony Hadla(The University of Melbourne), Rosanna Upstill‐Goddard(University of Glasgow), Anna DeFazio(The University of Sydney), David D.L. Bowtell(The University of Melbourne), James E. Vince(The University of Melbourne), Ulla‐Maja Bailey(Beatson West of Scotland Cancer Centre), Rosalind Glasspool(Institut Bergonié), Gareth Bryson(NHS Greater Glasgow and Clyde), Susanna L. Cooke(University of Glasgow), Patricia Roxburgh(Beatson West of Scotland Cancer Centre), Anthony T. Papenfuss(The University of Melbourne), Gayanie Ratnayake(Royal Women's Hospital), Justin Bedő(The University of Melbourne), Suzanne Dowson, Genevieve Dall(The University of Melbourne), Elizabeth L. Kyran(The University of Melbourne), Clare L. Scott(Walter and Eliza Hall Institute of Medical Research), S. John Weroha(Mayo Clinic), Iain A. McNeish(Imperial College London), Darren Ennis, Andrew V. Biankin(University of Glasgow), Nadia Traficante(The University of Melbourne), Orla McNally(Royal Women's Hospital), Matthew J. Wakefield(The University of Melbourne)
Cited by 26
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas
|New England Journal of Medicine|2010|1.7k
Whole–genome characterization of chemoresistant ovarian cancer
|Nature|2015|1.7k